Holocene Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $195M | Buy |
+596,816
| New | +$195M | 0.47% | 63 |
|
|
2023
Q2 | – | Sell |
-19,547
| Closed | -$3.92M | – | 704 |
|
|
2023
Q1 | $3.92M | Sell |
19,547
-579,381
| -97% | -$116M | 0.02% | 321 |
|
|
2022
Q4 | $142M | Sell |
598,928
-44,721
| -7% | -$10.6M | 0.87% | 28 |
|
|
2022
Q3 | $129M | Buy |
+643,649
| New | +$129M | 0.82% | 29 |
|
|
2022
Q2 | – | Sell |
-799,222
| Closed | -$131M | – | 799 |
|
|
2022
Q1 | $131M | Buy |
799,222
+76,483
| +11% | +$12.5M | 0.68% | 43 |
|
|
2021
Q4 | $123M | Buy |
722,739
+61,509
| +9% | +$10.4M | 0.64% | 45 |
|
|
2021
Q3 | $125M | Buy |
661,230
+105,991
| +19% | +$20M | 0.68% | 35 |
|
|
2021
Q2 | $94.1M | Buy |
+555,239
| New | +$94.1M | 0.53% | 56 |
|
|
2019
Q4 | – | Sell |
-117,988
| Closed | -$9.49M | – | 653 |
|
|
2019
Q3 | $9.49M | Buy |
+117,988
| New | +$9.49M | 0.1% | 125 |
|